RX Biosyent Inc

BioSyent Annual General Meeting of Shareholders - June 10, 2014

TORONTO, ONTARIO--(Marketwired - Jun 6, 2014) - BioSyent Inc. ("BioSyent") (TSX-VENTURE:RX) is pleased to announce that it will be holding its Annual General and Special Meeting of Shareholders at 9 a.m. EDT on Tuesday June 10, 2014 at the Sheraton Toronto Airport Hotel & Conference Centre (Niagara Room) located at 801 Dixon Road, Toronto, Ontario, M9W 1J5.

Following the formal business of the meeting, CEO René Goehrum will be making a presentation to attendees. Mr Goehrum will provide an overview of the Company and its corporate activities.

To view and listen to a CEO presentation commenting on First Quarter 2014 Financial Results released May 16, 2014, please visit the following link http://www.biosyent.com/q1/.

For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them.

Once a product of interest has been found, BioSyent then acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.

At the date of this press release the Company had 13,801,195 shares issued and outstanding.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.

BioSyent Inc.Mr. Rene C. GoehrumPresident and CEO(905) 206-0013investors@biosyent.comwww.biosyent.com